The Role of Peripheral Blood HIF-1α in Pancreatic Β-Cell Dysfunction and Insulin Resistance Among Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis

Why It Matters

Circulating HIF‑1α emerges as a potential biomarker of metabolic stress, offering clinicians a novel tool for risk stratification and informing therapeutic strategies targeting hypoxia pathways in type 2 diabetes.

Key Takeaways

• High peripheral HIF‑1α links to 1.13 mmol/L higher fasting glucose.
• Elevated HIF‑1α associated with 0.93 % increase in HbA1c.
• Patients with high HIF‑1α show 1.13 µU/mL higher fasting insulin.
• HOMA‑IR rises by 1.40 units when HIF‑1α is elevated.
• Non‑Chinese cohorts exhibit larger glucose effect than Chinese groups.

Pulse Analysis

Type 2 diabetes remains a global health crisis, with nearly 530 million adults affected in 2021 and projections exceeding 780 million by 2045. While hyperglycemia and insulin resistance are well‑characterized, the molecular drivers linking cellular hypoxia to metabolic dysfunction are less understood. Hypoxia‑inducible factor‑1α (HIF‑1α) orchestrates cellular adaptation to low oxygen, influencing glucose metabolism, oxidative stress, and inflammatory pathways. Recent genetic and mechanistic studies have implicated HIF‑1α in pancreatic β‑cell dedifferentiation and peripheral insulin resistance, prompting interest in its utility as a systemic marker of disease severity.

The meta‑analysis by Su et al. aggregates data from 36 cross‑sectional studies, revealing consistent associations between higher peripheral HIF‑1α and key glycemic indices: fasting plasma glucose, HbA1c, fasting insulin, and HOMA‑IR. Although heterogeneity was high (I² > 90 %), subgroup analyses suggest geographic variation, with non‑Chinese populations showing a markedly larger glucose effect. Importantly, sensitivity and publication‑bias assessments upheld the direction and magnitude of the relationships, underscoring the reliability of circulating HIF‑1α as an indicator of metabolic stress rather than a mere epiphenomenon.

Clinically, these findings open avenues for incorporating HIF‑1α measurement into routine diabetes monitoring, especially for patients at risk of rapid β‑cell decline or escalating insulin resistance. Future research should prioritize longitudinal cohorts and interventional trials to determine whether modulating HIF‑1α activity can preserve β‑cell function or improve insulin sensitivity. Integrating hypoxia‑targeted therapies with existing glucose‑lowering agents could refine personalized treatment strategies, ultimately mitigating the long‑term complications of type 2 diabetes.